Vigil Neuroscience reports promising interim results from its Phase 1 trial of VG-3927, showing a strong safety, tolerability, and pharmacokinetic profile in healthy volunteers. The data support continued development of VG-3927 as a potential daily oral therapy for Alzheimer's disease.
Read more